In the Claims:

Please amend the claims as follows:

1. (Currently Amended) A composition comprising *ex vivo* expanded CIK cells (defined as TH1 activated, non-MHC restricted cytotoxic T cells), wherein at least 2% of the expanded CIK cells are at least 2-fold more selective for ~~cells that selectively damage~~ damaging tumor-associated vasculatur cells compared to unstimulated PBMC cells ~~compared to normal vasculature~~ and a pharmaceutically acceptable carrier.

2. (Canceled).

3. (Original) The composition of claim 1 wherein the selectivity is at least 5-fold.

4. (Original) The composition of claim 1 wherein the selectivity is at least 100-fold.

5. (Canceled).

6. (Currenly Amended) The composition of claim 1 ~~5~~ wherein at least 5% of the ex vivo expanded CIK cells selectively kill tumor-associated vascular endothelial cells compared vascular endothelial cells associated with normal tissues.

Scoped only used HUVEC how do you screen for tumor specific clones?

7. (Currently Amended) The composition of claim 6 wherein at least 10% of the ex vivo expanded CIK cells selectively kill tumor-associated vascular endothelial cells compared vascular endothelial cells associated with normal tissues.

8. (Currently Amended) The composition of claim 6 wherein at least 50% of the ex vivo CIK expanded cells selectively kill tumor-associated vascular endothelial cells compared vascular endothelial cells associated with normal tissues.

9-13. (Canceled).

14. (Original) The composition of claim 12 or 13 wherein the antigen recognition is non-classical MHC restricted.

15. (Original) The composition of claim 12 or 13 wherein the antigen recognition is MHC-independent.

16. (Currently Amended) The composition of claim 1 wherein the ex vivo expanded CIK cells express a cell-surface receptor which recognizes heat shock protein 47 (Hsp47).

17. (Currently Amended) The composition of claim 1 wherein the ex vivo expanded CIK cells express a cell-surface receptor which recognizes HLA.

18. (Currently Amended) The composition of claim 1 wherein the ex vivo expanded CIK cells express a cell-surface receptor which recognizes IL-12 receptor ~~or a part thereof~~.

19. (Currently Amended) The composition of claim 1 wherein the ex vivo expanded CIK cells express a cell-surface receptor which recognizes a heat shock protein.

20. (Currently Amended) The composition of claim 1 wherein the ex vivo expanded CIK cells comprise cells expressing both CD3 and CD56.

21. (Original) The composition of claim 1 wherein the ex vivo expanded cells comprise cells that kill tumor cells.

22. (Original) The composition of claim 1 further comprising a chemotherapeutic compound.

23. (Canceled).

24. (Original) The composition of claim 1 wherein an agent binds to the ex vivo expanded cell non-covalently.

25. (Amended) The composition of claim 24 wherein the agent is a mono-, bi- or multi-specific antibody or molecular scaffold, directed with at least one binding activity to the CIK cell, and at least one other domain against a cancer cell or endothelial target.

26-59. (Canceled).

60. (New) A composition comprising *ex vivo* expanded CIK cells wherein at least 2% of the *ex vivo* expanded CIK cells kill cultured HUVEC cells in the absence, but not in the presence of Hsp47 and a pharmaceutically acceptable carrier.

61. (New) The composition of claim 60 wherein at least 5% of the *ex vivo* expanded CIK cells kill cultured HUVEC cells in the absence, but not in the presence of Hsp47.

62. (New) The composition of claim 60 wherein at least 10% of the CIK cells kill cultured HUVEC cells in the absence, but not in the presence of Hsp47.

63. (New) The composition of claim 60 wherein at least 50% of the CIK cells kill cultured HUVEC cells in the absence, but not in the presence of Hsp47.